Category Archives: Professional News

Heavy teen cannabis use and anxiety later in life

Via NDARC:

Teenagers who smoke cannabis weekly or more are twice as likely as non-users to have an anxiety disorder in their late 20s, even if they stop using, a study of 2000 Victorian teenagers has found.

Those who used frequently in their teens and continued to use on a daily basis at the age of 29 were three times as likely to have an anxiety disorder compared with non- or infrequent users. Those who used minimally in their teens but became daily users in their late 20s were two and a half times as likely to have an anxiety disorder. But the really striking finding say the authors is the persistent association between frequent teenage cannabis use and adult anxiety disorders up to a decade after cannabis use has ceased. The relationship between cannabis use and anxiety disorders was present even after the researchers took into account other possible explanations such as mental health problems in their teens or other drug use in their twenties.

The findings, published online in Addiction are based on secondary analyses of a landmark study of nearly 2000 Victorian secondary school students – the 2000 stories cohort, led by Professor George Patton of the Centre for Adolescent Health at the Murdoch Childrens Research Institute in Melbourne. The students have been followed up and interviewed over 13 years, starting in 1992. They were interviewed at six six-monthly intervals during their teens and then again when they were aged 20-21, 24-25, and 29.
Lead author of the analysis, Professor Louisa Degenhardt from the National Drug and Alcohol Research Centre at the University of New South Wales, said that most studies looking at cannabis use and mental health outcomes focus on adolescence and early adulthood. “What we are seeing is a persistent association with anxiety disorders over a much longer period. “Given that anxiety is the most prevalent mental health disorder in the Australian population, affecting over 14 per cent of adults in any 12 month period, we need to investigate the findings further because it is highly possible that early cannabis use causes enduring mental health risks.”

Professor Patton, lead investigator of the 2000 stories cohort, said that the findings could be explained by lasting changes to brain function caused by introducing cannabis at a time when the brain is developing rapidly. Equally it could be that the very factors which predispose people to use cannabis early also predispose them to common mental health problems. “We know from animal studies that introducing cannabis during puberty brings about long lasting changes in behaviour which persist even after administration of cannabis is stopped. These findings suggest that a similar thing may be happening,” said Professor Patton. “During the teen years the parts of the brain that are involved in managing emotions are still developing rapidly and it is highly possible that heavy cannabis use at this sensitive point could have long lasting effects.”
However the authors write that they cannot rule out the possibility that the factors that predispose people to use cannabis early also put them at risk for common mental disorders.
“These common factors might include biological, personality, social and environmental factors, or a combination of these factors. This is a plausible hypothesis because social disadvantage is more common among persons who are problematic substance users and who meet criteria for common mental disorders,” they write.

Degenhardt et al (2012). The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction (early online view).
http://onlinelibrary.wiley.com/doi/10.1111/j.1360-0443.2012.04015.x/pdf

ABI-AOD Forum – Victoria

Turning Point Statewide Neuropsychology Service

is pleased to invite you to

The Inaugural ABI-AOD Sector Forum.

Tuesday 4th September 2012, 3.30 – 5.00 p.m.

at Turning Point, 54 Gertrude St. Fitzroy.

 

 

We welcome Doutta Galla Community Health Service together with Will Di Palma and Janine Harvey (Service Integration Advisors) from the Multiple & Complex Needs Initiative. These agencies will jointly present a challenging case that highlights the difficulties encountered with managing comorbid ABI and AOD issues, together with extreme behavioural disturbance. There will be opportunity for discussion and networking is encouraged (bring your service brochures). Professional Development points may apply. This forum will be chaired by Professor Dan Lubman (Director, Turning Point Alcohol & Drug Centre).

 

The seminar is free. All welcome, bookings essential, ring 8413 8413 or email info@turningpoint.org.au

 

The ABI-AOD Forum will be a regular event, comprising the presentation of a complex case and panel discussion with multi-agency and multi-disciplinary involvement.

 

For more information contact Dr Karen Bird (03) 8413 8444, karenb@turningpoint.org.au  (Mon/Tue/Wed)

Alcohol Review Board: First Report

Information on the Alcohol Advertising Review Board, the full first report and the determinations can be found at www.alcoholadreview.com.au

 

MEDIA RELEASE

2 August 2012: FIRST REPORT OF ALCOHOL ADVERTISING REVIEW BOARD

 

Advertisements linking alcohol with AFL, NRL and fast cars, products likely to appeal to young women, the Jim Beam on Campus promotion targeting university students, and a “Woodstock Bourbon Calendar Babes” promotion are among alcohol advertisements criticised and recommended for withdrawal in a report released today.

 

The first report of the Alcohol Advertising Review Board (AARB) provides the outcomes of the first three months of determinations by the AARB. The AARB, which is chaired by Professor Fiona Stanley AC, was established in March by the McCusker Centre for Action on Alcohol and Youth and the Cancer Council WA, with the support of a wide range of health and related organisations.  The AARB considers and reviews complaints about alcohol advertising.  Its Code is based on codes already accepted by the alcohol and advertising industries in Australia or overseas.

 

In its first three months, the AARB received 63 complaints, 44 of which were considered appropriate for review by the AARB Panel.  Of these, 25 were upheld, and 17 upheld in part.

 

The AARB commends Bacardi Lion for responding by immediately withdrawing advertising close to a children’s playground.

 

Advertisements judged as contravening the Code included:

  • Advertising for alcoholic products considered to be of likely appeal to young people, with names such as “Pom Pom”, ”Electric Pink” and “Hot Pink”, and “Skinnygirl Cocktails”.
  • Event sponsorship including the Carlton Draught AFL sponsorship (Carlton Draught “Draught Pick” iPhone application, AFL tipping website and stadium promotions); Jim Beam and Jack Daniel’s sponsorship associating alcohol with fast cars; VB sponsorship of Surfing Australia; VB and XXXX beer State of Origin sponsorship (including a poster given to a school student featuring XXXX logos); placement of advertisements for alcohol products near schools; Smirnoff Vodka sponsorship of music festivals (including “Groovin’ the Moo”).
  • Promotion targeted at university students, including Jim Beam on Campus.
  • Advertisements for Jim Beam and Cola during AFL games and the Woodstock Bourbon and Cola “Woodstock Calendar Babes” promotion.

 

AARB Chair Professor Fiona Stanley said, “This shows a deeply disturbing range of alcohol advertising and promotion that simply should not be permitted”.

 

“What reason can there be to expose young people and children to the association of alcohol with their sporting heroes or with behaviours such as driving fast cars and surfing, to promote products in ways that must appeal to young people, and to promote alcohol on university campuses?

 

It cannot be responsible to advertise spirits in association with music festivals attended by young people, or to link alcohol with images of women in lingerie captioned ‘Wood U?’.  It is time to name and shame the companies that advertise alcohol irresponsibly and particularly to challenge them to promote their products in ways that do not appeal to young people”.

 

“In an Olympic week, the Gold medal for tasteless or inappropriate alcohol promotion goes to the Carlton Draught AFL sponsorship.  The Silver medal goes to the Jim Beam on Campus promotion which clearly targets young people and is associated with Facebook images that are utterly inappropriate, and the Bronze medal goes to Skinnygirl Cocktails which must be of appeal to young women.”

 

“We have no power to force the advertisements to be withdrawn, but we appeal to the companies to take seriously the concerns raised in the determinations of independent panels and change their promotional practices”.

 

Australian Medical Association Federal Vice-President Professor Geoff Dobb said, “The fact that alcohol companies continue to advertise in ways that are targeted to young people clearly shows that the current system of self-regulation does not work. The AMA believes that the alcohol industry has had its chance, it has failed to do the right thing, and now it is time for governments to act by regulating and prohibiting the marketing and promotion of alcohol to young people and teenagers.”

 

Director of the McCusker Centre for Action on Alcohol and Youth, Professor Mike Daube said, “It is time for alcohol companies to stop targeting younger drinkers. Some of the promotions highlighted in these complaints are outrageous. At a time when there is so much concern about the consequences of alcohol, surely this industry can make a genuine effort to protect children and young people from exposure to alcohol promotion.”

 

Some delays in the release of the first report arose from the need to deal with issues raised by representatives of major alcohol industry organisations. It was also considered appropriate to release the first three months of determinations as a set.  After this report’s release, determinations will be released as they are made.

 

Cancer Council WA Director of Research and Education Terry Slevin said, “The AARB gives concerned people a chance to challenge the way alcohol is advertised and promoted by holding alcohol companies to their own standards.

 

Alcohol cannot be treated just like any other product and greater controls are necessary on the way it is promoted and advertised. This cannot be left in the hands of the people who sell it.”

 

Information on the Alcohol Advertising Review Board, the full first report and the determinations can be found at www.alcoholadreview.com.au

 

Complaints about alcohol advertising can be sent to complaints@alcoholadreview.com.au.

Anthrax and Heroin Users: Important Information

Important info from the AIVL via INPUD:

 

INPUD Anthrax Alert for Heroin Users (Issue 1 – August 2012)

INPUD has produced some important guidance regarding the recent anthrax outbreaks among Heroin users in Europe, click on the following links to view, download and print the documents, and please distribute widely:

You’ll also find a page dedicated to keeping an up-to-date collection of information relating to this topic on AIVL’s website, including a complete report on the response in the UK during the 2009/10 outbreak. You can find all this information and more at http://www.aivl.org.au/#p=17984.

National Workforce Development Fund – Subsidised Training

Odyssey House Victoria – National Workforce Development Fund – Subsidised Training

Odyssey House Victoria has been awarded a funding contract for training alcohol and other drug workers under the National Workforce Development Fund.

The funding enables organisations like yours to up-skill their employee qualifications in alcohol and other drugs work. The funding subsidises the cost of training up to 67%, with the remainder co-contribution from employers.

We can assist your organisation with qualifications such as Certificate IV in Alcohol and Other Drugs Work (CHC40412), Diploma Alcohol and Other Drugs Work (CHC50212) and the Diploma Alcohol and Other Drugs Work and Mental Health (CHC50412)

To find out more about accessing this funding subsidy with Odyssey House Victoria please complete the brief enquiry form here www.workskillsweb.net/forms/view.php?id=58and we will contact you.

Symposium Scholarships

The Foundation for Alcohol Research & Education (FARE), formerly known as the Alcohol Education & Rehabilitation Foundation, has partnered with the ATCA to support the attendance of workers in the alcohol and other drug field at the upcoming ATCA symposium in to be held in Launceston in August.

Sponsorship is available for organisations that pursue best-practice goals by developing the knowledge and expertise of staff that work in the alcohol and other drug sector. Organisations need to demonstrate the benefits that staff will gain through attendance at the symposium.

While a number of the scholarships have been taken up, there is some funding available for attendance, with 1 person per organisation eligible to receive funding.  Justification of the expenditure items proposed must be provided at the time of applying for the scholarship funding round.

Symposium Attendance Sponsorship will cover:

•    Necessary travel to the location of the symposium by rural and remote workers and early career researchers;

•    Accommodation close to the symposium to reduce daily travel;

•   Symposium Registration (standard price and Symposium Dinner);

Symposium Attendance Sponsorship will not cover:

•   Travel allowance including meals (except symposium dinner)

•    Backfill of positions during conferences

•    Airport transfers

 

This project aims to:

•      Assist individuals in rural and remote Australia to attend the conference.

•     Assist new researchers (in the first three years of their career) to attend the symposium.

 

The ATCA Board and Symposium Organising Committee invites organisations and individuals who believe they fit the criteria to apply for funding.  Further details are available by contacting Lynne Magor-Blatch by email: atca@atca.com.au

2012 National Drug Trends Conference

2012 National Drug Trends Conference

National Maritime Museum, Darling Harbour, Sydney

8.00am – 4.00pm

Tuesday 9th October 2012

Drugs, crime and the front line: Australasian Perspective

 

The National Drug Trends Conference will present recent findings in illicit drug use, markets and related harms across Australia. Convened by Australia’s largest drug monitoring systems, the Illicit Drug Reporting System (IDRS) and the Ecstasy and Related Drugs Reporting System (EDRS), the one day conference will include the first release of the 2012 findings.

We are also delighted to announce that there will be presentations from a number of distinguished international and national guest speakers, including Mr Gary Lewis (UNODC), Dr Chris Wilkins (SHORE, Massey University, NZ), Dr Malcolm Dobbin (Dept of Health, VIC), Dr Marianne Jauncey (MSIC), Dr Alex Wodak (St Vincents Hospital), Mr Peter Bowron (Toxicology Unit, Macquarie Hospital), Dr David Bright (UNSW), Ms Claire Rickards (NSW Police), Ms Annie Madden (AIVL), Dr Raimondo Bruno (UTAS), and Ms Amanda Roxburgh (NDARC).

Talks will include IDRS and EDRS:

  • 2012 Illicit Drug Reporting System – National key findings
  • 2012 Ecstasy and Related Drug Reporting System – National Key Findings
  • Online drug use and purchase patterns among regular ecstasy users (EDRS) nationally in 2012

International guest speakers

Mr Gary Lewis –  United Nations Office on Drugs and Crime
Dr Chris Wilkins – Illicit Drug Monitoring System in New Zealand

Local guest speakers

Ms Annie Madden – Consumer Perspectives from Australian and overseas
Dr Marianne Jauncey – Yearly Trends and Front-Line Issues experience at MSIC
Mr Peter Bowron – Current Trends in Drugs Tested at the Toxicology Unit
Dr Alex Wodak – The Changing Nature of Substance Use in the Darlinghurst Area
Ms Claire Rickards – High Level Organised Crime, Drug Trends of Heroin and Other Opioids

Dr David Bright – The Strengths and Vulnerabilities of Drug Trafficking Networks

Dr Malcolm Dobbin – Systems to Coordinate Supply of Dangerous Medicines

Dr Raimondo Bruno – Water Waste Technology

Ms Amanda Roxburgh – Pharmaceutical Opioids and Fentanyl

Registration

To register please see the conference website http://www.cvent.com/events/national-drug-trends-conference-2012/invitation-ee34d144a427422d943081a00893db7b.aspx

Registration Cost

Conference costs
Registration $250
Student $200
Cancellation fee $80

The IDRS and EDRS are funded by the Australian Government Department of Health and Ageing.

 

We look forward to seeing you in Sydney!

Guide to the Australian Alcohol Industry

Interesting new publication:

The McCusker Centre for Action on Alcohol and Youth has developed a guide to the alcohol industry in Australia and how it fits into the global alcohol industry, and a guide to the major alcohol sales outlets in Australia.

The guide to the alcohol industry in Australia outlines the major alcohol companies and the products they produce, own, distribute or market.
The information has been collated and summarised from a wide range of sources including alcohol company websites and annual reports. Due to the constantly changing nature of the industry, this document should be taken as a guide only.

We welcome feedback or suggestions and will endeavour to regularly update the information.

The guides are available to download from the McCusker Centre website at http://www.mcaay.org.au/publications.html

PhD scholarship opportunity: Melbourne

PhD Scholarship: Qualitative research on injecting drug use in Melbourne

 

EXPRESSION OF INTEREST

The National Drug Research Institute (NDRI) invites expressions of interest from suitably qualified candidates for a PhD scholarship in qualitative research on injecting drug use in Melbourne. The project is one component of an NHMRC-funded Centre for Research Excellence on Injecting Drug Use. The collaborative, multidisciplinary centre involves researchers from NDRI; the Burnet Institute; the National Drug and Alcohol Research Centre; the Kirby Institute; Turning Point Alcohol and Drug Centre; and the University of Queensland.

 

The scholarship carries an annual tax-free stipend of $29,424 a year for three years. The scholarship will start as soon as possible and is based at NDRI’s Melbourne office, located at Turning Point Alcohol and Drug Centre in Fitzroy. There is also possibility of additional paid work.

 

Deadline and application details at http://ndri.curtin.edu.au/students/phd-mel.cfm

WHO on Hep B and C

The World Health Organization (WHO) has identified four key actions countries can take to prevent viral hepatitis B and C among people who inject drugs.  Of the estimated 16 million people who inject drugs worldwide, it is estimated that 10 million are infected with hepatitis C. An additional 1.2 million are infected with hepatitis B.

Risk from shared syringes and needles

Many drug users are unable to obtain sterile syringes: in some countries it is illegal to distribute or possess syringes for non-medical purposes. The risk of contracting hepatitis and HIV infection occurs when people share syringes and needles. Used injection equipment retains traces of blood. If that blood contains HIV, hepatitis or another type of virus, the next person using the syringe could be infected.

Reducing the risk of HIV and hepatitis infections

A number of countries have established programmes to reduce HIV infections among people who inject drugs.

“Most of the interventions that prevent HIV transmission between people who inject drugs are virtually the same as those for preventing viral hepatitis B and C,” says Dr Gottfried Hirnschall, Director of the WHO Department for HIV/AIDS. “So it makes sense to reduce the risk of both infections by linking viral hepatitis prevention with HIV prevention, care and treatment.”

Hepatitis is an inflammation of the liver. Together, hepatitis B and C are the most common cause of cirrhosis and cancer of the liver. Viral hepatitis progresses faster among people living with HIV because their immune systems are weaker, and causes more severe liver-related health problems than it does among people without HIV infection.

WHO recommendations

WHO recommends:

  • Implementing and scaling up HIV prevention programmes such as clean needle and syringe programmes and opioid substitution therapy (treatment of opioid dependence with methadone or buprenophine).
  • Offering people who inject drugs the rapid hepatitis B vaccination regimen (completed in 3 weeks instead of 6 months), along with incentives to increase uptake and completion of the vaccine schedule. More than 175 countries now include a cheap, safe and effective vaccine against hepatitis B in their national infant immunization schedules.  WHO has already recommended countries provide catch-up vaccination for people at increased risk of hepatitis infection, including injection drug users, but this does still not occur systematically at present. There is no vaccine against hepatitis C.
  • Using “low dead space” syringes that retain less  blood after use reduces the survival of HIV and hepatitis C in the blood that remains in the syringe. This  potentially reduces the risk of transmission if injecting equipment is shared.
  • Involving drug users in hepatitis prevention programmes to maximize their impact.

Public health approach

“Countries that have adopted a public health approach to injecting drug use and HIV have been the most successful in turning round their HIV epidemics. We need to do the same for hepatitis,” says Dr Ying-Ru Lo of the HIV Department at WHO.

The new evidence-based guidelines are designed for use by national public health officials, managers of HIV, drug dependence and harm reduction programmes, civil society and health workers in low- and middle-income countries. They are intended to be tailored and implemented according to local situations and needs.

Notes to editors:

The XIX International AIDS Conference is taking place in Washington D.C. 22-27 July 2012. The theme of the conference is “Turning the Tide Together”. WHO is presenting proposals to accelerate the end  of HIV transmission. This includes a discussion paper on strategic use of antiretrovirals (ARVs), a global report on drug resistance, guidance on the prevention and treatment of HIV and STIs among sex workers, and guidance on the use of ARVs as Pre-Exposure Prophylaxis (PrEP) among people at particularly high risk of HIV.

Full guideline document on the prevention of viral hepatitis B and C and HIV among people who inject drugs is available at: http://www.who.int/hiv/pub/guidelines/hepatitis/en/

And more information on HIV in people who inject drugs and harm reduction at
http://www.who.int/hiv/topics/idu/en/index.html